News for BioCardia, Inc. (BCDA)

CardiAMP HF II is Evaluating the CardiAMPâ„¢ Cell Therapy Product for Treating Patients with Ischemic Heart Failure of Reduced Ejection Fraction and Elevated Ma

BioCardia, Inc. (BCDA) has initiated patient enrollment at Emory University School of Medicine in Atlanta, Georgia for its pivotal Phase III CardiAMP HF II stud

BioCardia (BCDA) has started patient enrollment at Emory University School of Medicine for its CardiAMP HF II Phase III trial. The trial aims to evaluat

**media[592649]**

Company positions for long-term growth in medical device markets Salt Lake City, UT, April 03, 2025 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. ( SINT), an

BioCardia shares promising results from the CardiAMP Heart Failure trial, showing reduced mortality risks and improved quality of life.

BioCardia, Inc. (NASDAQ:BCDA) Q4 2024 Earnings Conference Call March 31, 2025 4:30 PM ETCompany ParticipantsMiranda Peto - Investor RelationsPeter Altman -...

**media[581871]**

**media[577781]**

BioCardia Inc (BCDA) is set to release its Q4 2024 earnings on Mar 26, 2025. The consensus estimate for Q4 2024 revenue is $0.02 million, and the earnings are e

SUNNYVALE, Calif., Jan. 27, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. [ BCDA] today announced that the results of its double-blind randomized placebo-controlle

Next PMDA Consultation after Review of CardiAMP HF Trial Data SUNNYVALE, Calif., Dec. 04, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. [ BCDA], a global leader

BioCardia stock plunges to 52-week low, touches $1.93

BioCardia, Inc. (NASDAQ:BCDA) Q3 2024 Earnings Conference Call November 13, 2024 4:30 PM ETCompany ParticipantsMiranda Peto - Investor RelationsPeter Altman...

**media[465419]**

Revenue: $3,000 for Q2 2024, compared to $43,000 for Q2 2023.Expenses: Decreased by 53% quarter-over-quarter.Research and Development Expenses: $800,000 in Q2

Aug 13, 2024 / 08:30PM GMTOperator Ladies and gentlemen, thank you for standing by. Good afternoon. And welcome to the BioCardia second quarter 2024 financial r

SUNNYVALE, Calif., Sept. 18, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. (NASDAQ:BCDA), a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, announced today

Texas-based Beneficient (BENF) is up over 92 percent in Friday's pre-market trading. The following are some of the other stocks making big moves in Friday's pre-market trading.